• ASO Visual Abstract: Incidence of Occult Breast Cancer in Carriers of BRCA1/2 and Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy-When is Sentinel Lymph Node Biopsy Indicated?
    • Wong SM, Ferroum A, Apostolova C, Alhassan B, Prakash I, Basik M, Boileau JF, Meterissian S, Aleynikova O, Wong N, Foulkes WD.
    • Ann Surg Oncol. 2022 Oct;29(11):6671-6672. doi: 10.1245/s10434-022-12011-3.
    • Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer.
    • Ip E, Young AL, Scheinberg T, Harrison M, Beale P, Goodwin A.
    • Asia Pac J Clin Oncol. 2022 Oct;18(5):e414-e419. doi: 10.1111/ajco.13741. Epub 2022 Jan 30.
    • Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing.
    • Fallowfield L, Solis-Trapala I, Starkings R, May S, Matthews L, Eccles D, Evans DG, Turnbull C, Crawford G, Jenkins V.
    • Br J Cancer. 2022 Oct;127(6):1116-1122. doi: 10.1038/s41416-022-01871-x. Epub 2022 Jun 17.
    • Integrating hereditary breast and ovarian cancer genetic counselling and testing into mainstream clinical practice: Legal and ethical challenges.
    • Charron M, Kaiser B, Dauge A, Gallois H, Lapointe J, Dorval M, Nabi H, Joly Y.
    • Crit Rev Oncol Hematol. 2022 Oct;178:103797. doi: 10.1016/j.critrevonc.2022.103797. Epub 2022 Aug 27.
    • Review
    • Patient Understanding of Tumor Genomic Testing: A Quality Improvement Effort.
    • Senter L, Veney D, Surplus T, Haynam M, Adams EJ, Hampel H, Toland AE, Presley CJ, Padamsee TJ, Lee CN, Hovick SR, Stover DG.
    • JCO Oncol Pract. 2022 Sep 21:OP2200316. doi: 10.1200/OP.22.00316. Epub ahead of print.
    • Points to Consider Regarding De-Escalation Surgery in High-Risk Breast Cancer.
    • Corso G, Magnoni F, Veronesi P.
    • Ann Surg Oncol. 2022 Sep 15. doi: 10.1245/s10434-022-12542-9. Epub ahead of print.
    • Review
    • Current status of hereditary breast and ovarian cancer practice among gynecologic oncologists in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO).
    • Kobayashi Y, Masuda K, Hiraswa A, Takehara K, Tsuda H, Watanabe Y, Oda K, Nagase S, Mandai M, Okamoto A, Yaegashi N, Mikami M, Enomoto T, Aoki D, Katabuchi H; Working Group on Clinical Practice for Cancer Genomic Medicine and HBOC, Japan Society of Gynecologic Oncology.
    • J Gynecol Oncol. 2022 Sep;33(5):e61. doi: 10.3802/jgo.2022.33.e61. Epub 2022 Jul 18.
    • Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective.
    • Bokkers K, Frederix GWJ, Velthuizen ME, van der Aa M, Gerestein CG, van Dorst EBL, Lange JG, Louwers JA, Koole W, Zweemer RP, Ausems MGEM.
    • Gynecol Oncol. 2022 Aug 25:S0090-8258(22)00550-9. doi: 10.1016/j.ygyno.2022.08.011. Epub ahead of print. Epub ahead of print.
    • Myriad Genetics, Clarified Precision Medicine Team up on Molecular Tumor Board Service.
    • [No author given]
    • GenomeWeb. Disease Areas. Cancer. 2022 Aug 24.
    • A Woman Needs to Know She Is a BRCA Carrier Before She Develops Breast Cancer.
    • Hughes KS, Yin K.
    • Ann Surg Oncol. 2022 Aug;29(8):4667-4669. doi: 10.1245/s10434-022-11860-2. Epub 2022 May 12.

    Original research:

    Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy.

    • Risk-reducing Salpingo-oophorectomy consults and practices during the COVID-19 pandemic.
    • O'Mara AE, Benedict C, Kurian AW, Wagner SK, Diver E.
    • Gynecol Oncol Rep. 2022 Aug;42:101036. doi: 10.1016/j.gore.2022.101036. Epub 2022 Jun 28.
    • Views of Israeli healthcare professionals regarding communication of genetic variants of uncertain significance to patients.
    • Levin Fridman A, Raz A, Timmermans S, Shkedi-Rafid S.
    • J Genet Couns. 2022 Aug;31(4):912-921. doi: 10.1002/jgc4.1560. Epub 2022 Feb 4.
    • Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting.
    • Everett JN, Dettwyler SA, Jing X, Stender C, Schmitter M, Baptiste A, Chun J, Kawaler EA, Khanna LG, Gross SA, Gonda TA, Beri N, Oberstein PE, Simeone DM.
    • Cancer Med. 2022 Jul 30. doi: 10.1002/cam4.5059. Epub ahead of print.
    • Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeinschaft Gynäkologische Onkologie intergroup analysis.
    • Nguyen-Sträuli BD, Baum J, Meyer-Wilmes P, Kreklau A, Buschmann C, El Ouardi N, Fotopoulou C, Hummel M, Chekerov R, Braicu E, Sehouli J, Pietzner K.
    • Int J Gynecol Cancer. 2022 Jul 27:ijgc-2022-003637. doi: 10.1136/ijgc-2022-003637. Epub ahead of print.
    • Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
    • Chiu PKF, Lee EKC, Chan MTY, Chan WHC, Cheung MH, Lam MHC, Ma ESK, Poon DMC.
    • Front Oncol. 2022 Jul 18;12:962958. doi: 10.3389/fonc.2022.962958.
    • Surgical Management of Inherited Breast Cancer: Role of Breast-Conserving Surgery.
    • Magnoni F, Sacchini V, Veronesi P, Bianchi B, Bottazzoli E, Tagliaferri V, Mazzotta E, Castelnovo G, Deguidi G, Rossi EMC, Corso G.
    • Cancers (Basel). 2022 Jul 1;14(13):3245. doi: 10.3390/cancers14133245.
    • Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer.
    • Bokkers K, Zweemer RP, Koudijs MJ, Stehouwer S, Velthuizen ME, Bleiker EMA, Ausems MGEM.
    • Fam Cancer. 2022 Jul;21(3):295-304. doi: 10.1007/s10689-021-00277-7. Epub 2021 Oct 7.
    • Can Automated Alerts in the Electronic Health Record Encourage Referrals for Genetic Counseling and Testing Among Patients at High Risk for Hereditary Cancer Syndromes?
    • Zorn KK, Simonson ME, Faulkner JL, Carr CL, Acuna J, Hall TL, Jenkins JF, Drummond KL, Curran GM.
    • JCO Oncol Pract. 2022 Jul;18(7):e1219-e1224. doi: 10.1200/OP.21.00641. Epub 2022 Mar 22.
    • Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.
    • McGuire KP, Arthur DW, Mamounas EP.
    • Ann Surg Oncol. 2022 Jun 18. doi: 10.1245/s10434-022-12048-4. Epub ahead of print.

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    Summary, Review:

    Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.

    Guideline:

    Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.

    • Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.
    • Ramsey ML, Tomlinson J, Pearlman R, Abushahin L, Aeilts A, Chen HZ, Chen Y, Compton A, Elkhatib R, Geiger L, Hays J, Jeter J, Jin N, Malalur P, Roychowdhury S, Ruple J, Prebish J, Stanich PP, Hampel H.
    • Fam Cancer. 2022 Jun 17. doi: 10.1007/s10689-022-00300-5. Epub ahead of print.
    • Programmatic Efforts Increase Adoption of Genomic Precision Medicine in Cancer Care in a Community Cancer Center.
    • Darabi S, Braxton D, Homer J, Brodie T, Holnagel D, Eisenberg B, Demeure MJ.
    • JCO Precis Oncol. 2022 Jun;6:e2200090. doi: 10.1200/PO.22.00090.
    • Utilization of genetic testing: Analysis of 4,499 prior authorization requests for molecular genetic tests at four US regional health plans.
    • Bajguz D, Danylchuk NR, Czarniecki M, Selig JP, Sutphen R, Kaylor J.
    • J Genet Couns. 2022 Jun;31(3):771-780. doi: 10.1002/jgc4.1543. Epub 2021 Dec 23.
    • Breast cancer risk for transgender men with inherited mutations.
    • [No author given]
    • FORCE. XRAY. 2022 May 19.

    Commentary:

    BRCA Mutations and the Implications in Transgender Individuals Undergoing Top Surgery: An Operative Dilemma.

    • Healthcare professionals' perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups.
    • Witjes VM, Braspenning JCC, Hoogerbrugge N, Smolders YHCM, Hermkens DMA, Mourits MJE, Ligtenberg MJL, Ausems MGEM, de Hullu JA.
    • Fam Cancer. 2022 May 16. doi: 10.1007/s10689-022-00294-0. Epub ahead of print.
    • Attitudes and training needs of oncologists and surgeons in mainstreaming breast cancer genetic counseling in a low-to-middle income Asian country.
    • Lee YQ, Yoon SY, Hassan T, Padmanabhan H, Yip CH, Keng WT, Thong MK, Ahmad Annuar MA, Mohd Taib NA, Teo SH.
    • J Genet Couns. 2022 Apr 28. doi: 10.1002/jgc4.1579. Epub ahead of print.
    • Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context.
    • Kolinsky MP, Niederhoffer KY, Kwan EM, Hotte SJ, Hamilou Z, Yip SM, Chi KN, Wyatt AW, Saad F.
    • Can Urol Assoc J. 2022 Apr;16(4):132-143. doi: 10.5489/cuaj.7621.
    • Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice.
    • Giri VN, Walker A, Gross L, Trabulsi EJ, Lallas CD, Kelly WK, Gomella LG, Fischer C, Loeb S.
    • Clin Genitourin Cancer. 2022 Apr;20(2):e104-e113. doi: 10.1016/j.clgc.2021.11.009. Epub 2021 Nov 27.
    • Pilot study of an online training program to increase genetic literacy and communication skills in oncology healthcare professionals discussing BRCA1/2 genetic testing with breast and ovarian cancer patients.
    • Meiser B, Woodward P, Gleeson M, Kentwell M, Fan HM, Antill Y, Butow PN, Boyle F, Best M, Taylor N, Bell K, Tucker K.
    • Fam Cancer. 2022 Apr;21(2):157-166. doi: 10.1007/s10689-021-00261-1. Epub 2021 May 10.
    • Awareness of genetic counseling and genetic testing for hereditary gynecologic cancers among Korean healthcare providers: A survey.
    • Kim M, Cheol Lim M, Ji Nam E, Huang D, Kim S, Jong Yoo H, Lee YY, Chang YJ; on the behalf of the sub-committee of Hereditary Gynecologic Cancers in the Korean Society of Gynecologic Oncology (KSGO).
    • J Genet Couns. 2022 Apr;31(2):546-553. doi: 10.1002/jgc4.1524. Epub 2021 Oct 21.
    • Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model.
    • Azzollini J, Vingiani A, Agnelli L, Tamborini E, Perrone F, Conca E, Capone I, Busico A, Peissel B, Rosina E, Ducceschi M, Mantiero M, Lopez S, Raspagliesi F, Niger M, Duca M, Damian S, Proto C, de Braud F, Pruneri G, Manoukian S.
    • Front Oncol. 2022 Apr 8;12:857515. doi: 10.3389/fonc.2022.857515.
    • Myriad Genetics Launches New Comprehensive Suite of Cancer Tests With Research Registry.
    • Ray T.
    • GenomeWeb. Business & Policy. Business News. 2022 Mar 14.
    • News

    Press Release: Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care. (Myriad Genetics)

    • Real-world multi-country study of BRCA1/2 mutation testing among adult women with HER2-negative advanced breast cancer.
    • Lux MP, Lewis K, Rider A, Niyazov A.
    • Future Oncol. 2022 Mar;18(9):1089-1101. doi: 10.2217/fon-2021-1387. Epub 2022 Jan 31.
    • Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan.
    • Leith A, Ribbands A, Kim J, Last M, Barlow S, Yang L, Ghate SR.
    • Future Oncol. 2022 Mar;18(8):937-951. doi: 10.2217/fon-2021-1113. Epub 2022 Jan 19.
    • Retrospective assessment of barriers and access to genetic services for hereditary cancer syndromes in an integrated health care delivery system.
    • Muessig KR, Zepp JM, Keast E, Shuster EE, Reyes AA, Arnold B, Ingphakorn C, Gilmore MJ, Kauffman TL, Hunter JE, Knerr S, Feigelson HS, Goddard KAB.
    • Hered Cancer Clin Pract. 2022 Feb 10;20(1):7. doi: 10.1186/s13053-022-00213-5.
    • "It was an important part of my treatment": a qualitative study of Norwegian breast Cancer patients' experiences with mainstreamed genetic testing.
    • Strømsvik N, Olsson P, Gravdehaug B, Lurås H, Schlichting E, Jørgensen K, Wangensteen T, Vamre T, Heramb C, Mæhle L, Grindedal EM.
    • Hered Cancer Clin Pract. 2022 Feb 5;20(1):6. doi: 10.1186/s13053-022-00212-6.
    • Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany.
    • Lux MP, Decker T, Runkel ED, Niyazov A, Quek RGW, Marschner N, Harbeck N.
    • Breast Care (Basel). 2022 Feb;17(1):40-46. doi: 10.1159/000513596. Epub 2021 Feb 18.
    • Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
    • Stone RL, Cambron-Mellott MJ, Beusterien K, Maculaitis MC, Ritz S, Mulvihill E, Monberg M, Szamreta EA, Amin S, McLaurin K.
    • Future Oncol. 2022 Feb;18(4):491-503. doi: 10.2217/fon-2021-0567. Epub 2021 Dec 8.
    • Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants.
    • Douglas MP, Lin GA, Trosman JR, Phillips KA.
    • J Community Genet. 2022 Feb;13(1):75-80. doi: 10.1007/s12687-021-00563-y. Epub 2021 Nov 6.
    • Physicians' experience, practice and education, on genetic testing and genetic counseling: a nationwide survey study in Greece.
    • Fountzilas E, Apostolou P, Vasiliadis AV, Aivazi D, Saloustros E, Fostira F.
    • Fam Cancer. 2022 Jan 24. doi: 10.1007/s10689-022-00290-4. Epub ahead of print.
    • BRCA Mutations and the Implications in Transgender Individuals Undergoing Top Surgery: An Operative Dilemma.
    • Jaber C, Ralph O, Hamidian Jahromi A.
    • Plast Reconstr Surg Glob Open. 2022 Jan 10;10(1):e4012. doi: 10.1097/GOX.0000000000004012.

    Research news: Breast cancer risk for transgender men with inherited mutations. (FORCE. XRAY)

    • Barriers Exist to Cancer Genetic Testing for Black Women, Survey Shows.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Jan 5.

    Original research:

    Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists.

    • Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance.
    • Cham S, Landrum MB, Keating NL, Armstrong J, Wright AA.
    • JAMA Netw Open. 2022 Jan 4;5(1):e2142703. doi: 10.1001/jamanetworkopen.2021.42703.

    News: BRCA Testing Underused in Women With Ovarian Cancer (Medscape)

    • Mainstreaming Genetic Testing for Epithelial Ovarian Cancer by Oncology Providers: A Survey of Current Practice.
    • Czekalski MA, Huziak RC, Durst AL, Taylor S, Mai PL.
    • JCO Precis Oncol. 2022 Jan;6:e2100409. doi: 10.1200/PO.21.00409.
    • Genetic Counseling, Screening and Risk-Reducing Surgery in Patients with Primary Breast Cancer and Germline BRCA Mutations: Unmet Needs in Low- and Middle-Income Countries.
    • Moukadem HA, Al Masry A, Atwani RW, Kreidieh F, Khalil LE, Saroufim R, Daouk S, Dalle IA, El Saghir NS.
    • Eur J Breast Health. 2021 Dec 30;18(1):16-20. doi: 10.4274/ejbh.galenos.2021.2021-5-1.
    • Genetic Testing Challenges in Oncology: Prior Retinoblastoma Not Considered in Test Ordering.
    • Ray T.
    • Precision Oncology News. Disease Areas. 2021 Dec 22.
    • Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists.
    • Ademuyiwa FO, Salyer P, Tao Y, Luo J, Hensing WL, Afolalu A, Peterson LL, Weilbaecher K, Housten AJ, Baumann AA, Desai M, Jones S, Linnenbringer E, Plichta J, Bierut L.
    • J Clin Oncol. 2021 Dec 20;39(36):4020-4028. doi: 10.1200/JCO.21.01426. Epub 2021 Oct 18.

    Commentary:

    Acknowledging Disparities in Hereditary Cancer Testing.

    Press: Physician Bias May Contribute to Lower Genetic Testing Rates Among Black Women, Study Suggests. (Precision Oncology News)

    Press: Barriers Exist to Cancer Genetic Testing for Black Women, Survey Shows. (Inside Precision Medicine)

    • Real-World Data Points to Racial Disparity in BRCA1/2 Testing Among TNBC Patients.
    • Ray T.
    • GenomeWeb. 2021 Dec 10.
    • Comparison of a Cancer Family History Collection and Risk Assessment Tool - ItRunsInMyFamily - with Risk Assessment by Health-Care Professionals.
    • Ritchie JB, Welch BM, Allen CG, Frey LJ, Morrison H, Schiffman JD, Alekseyenko AV, Dean B, Hughes Halbert C, Bellcross C.
    • Public Health Genomics. 2021 Dec 6:1-9. doi: 10.1159/000520001. Epub ahead of print.
    • Genetic Testing Challenges in Oncology: No Follow-up on Insurer Denial Delays Cancer Risk Management.
    • Ray T.
    • Precision Oncology News. Cancer Specialties. Breast Cancer. 2021 Nov 29.
    • Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study.
    • Elsamany S, Elbaiomy M, Zeeneldin A, Tashkandi E, Hassanin F, Abdelhafeez N, O Al-Shamsi H, Bukhari N, Elemam O.
    • JMIR Cancer. 2021 Nov 15;7(4):e27073. doi: 10.2196/27073.
    • Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer.
    • Hamilton JG, Symecko H, Spielman K, Breen K, Mueller R, Catchings A, Trottier M, Salo-Mullen EE, Shah I, Arutyunova A, Batson M, Gebert R, Pundock S, Schofield E, Offit K, Stadler ZK, Cadoo K, Carlo MI, Narayan V, Reiss KA, Robson ME, Domchek SM.
    • Genet Med. 2021 Nov;23(11):2105-2113. doi: 10.1038/s41436-021-01262-2. Epub 2021 Jul 13.
    • Germline Testing in Prostate Cancer: When and Who to Test.
    • Sokolova A, Cheng H.
    • Oncology (Williston Park). 2021 Oct 20;35(10):645-653. doi: 10.46883/ONC.2021.3510.0645.
    • Communicating polygenic risk scores in the familial breast cancer clinic.
    • Das Gupta K, Gregory G, Meiser B, Kaur R, Scheepers-Joynt M, McInerny S, Taylor S, Barlow-Stewart K, Antill Y, Salmon L, Smyth C, McInerney-Leo A, Young MA, James PA, Yanes T.
    • Patient Educ Couns. 2021 Oct;104(10):2512-2521. doi: 10.1016/j.pec.2021.02.046. Epub 2021 Mar 1.
    • Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing.
    • Wang Y, Golesworthy B, Cuggia A, Domecq C, Chaudhury P, Barkun J, Metrakos P, Asselah J, Bouganim N, Gao ZH, Chong G, Foulkes WD, Zogopoulos G.
    • J Med Genet. 2021 Sep 23:jmedgenet-2021-108054. doi: 10.1136/jmedgenet-2021-108054. Epub ahead of print.
    • Management of breast cancer patients with BRCA gene mutations in Lebanon of the Middle East: perspectives and challenges.
    • El Saghir NS, Ghanem H, El Karak F, Farhat F, Ghosn M, Makdessi J, Chouaib K, Debs J, Tabchy AB.
    • Hosp Pract (1995). 2021 Sep 22:1-5. doi: 10.1080/21548331.2021.1974678. Epub ahead of print.
    • Commentary
    • Reproductive issues in carriers of germline pathogenic variants in the BRCA1/2 genes: an expert meeting.
    • Buonomo B, Massarotti C, Dellino M, Anserini P, Ferrari A, Campanella M, Magnotti M, De Stefano C, Peccatori FA, Lambertini M.
    • BMC Med. 2021 Sep 10;19(1):205. doi: 10.1186/s12916-021-02081-7.
    • Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.
    • Kim SR, Tone A, Kim RH, Cesari M, Clarke BA, Eiriksson L, Hart TL, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE.
    • Cancer. 2021 Sep 1;127(17):3082-3091. doi: 10.1002/cncr.33625. Epub 2021 May 13.
    • Genetic testing in patients with triple-negative or hereditary breast cancer.
    • Bernstein-Molho R, Evron E, Yerushalmi R, Paluch-Shimon S.
    • Curr Opin Oncol. 2021 Sep 1. doi: 10.1097/CCO.0000000000000784. Epub ahead of print.
    • Review
    • Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study.
    • Chandrasekaran D, Sobocan M, Blyuss O, Miller RE, Evans O, Crusz SM, Mills-Baldock T, Sun L, Hammond RFL, Gaba F, Jenkins LA, Ahmed M, Kumar A, Jeyarajah A, Lawrence AC, Brockbank E, Phadnis S, Quigley M, El Khouly F, Wuntakal R, Faruqi A, Trevisan G, Casey L, Burghel GJ, Schlecht H, Bulman M, Smith P, Bowers NL, Legood R, Lockley M, Wallace A, Singh N, Evans DG, Manchanda R.
    • Cancers (Basel). 2021 Aug 27;13(17):4344. doi: 10.3390/cancers13174344.
    • Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics.
    • Sturgill EG, Misch A, Lachs R, Jones CC, Schlauch D, Jones SF, Shastry M, Yardley DA, Burris HA 3rd, Spigel DR, Hamilton EP, McKenzie AJ.
    • JCO Precis Oncol. 2021 Nov [Epub 2021 Aug 19];5:1297-1311. doi: 10.1200/PO.20.00469.

    Press: NGS Use for Breast Cancer Increases Sixfold in Community Oncology Clinics, Study Finds. (Precision Oncology News)

    • Effect of a health literacy training program for surgical oncologists and specialized nurses on disparities in referral to breast cancer genetic testing.
    • van der Giessen JAM, van Dulmen S, Velthuizen ME, van den Muijsenbergh METC, van Engelen K, Collée M, van Dalen T, Aalfs CM, Hooning MJ, Spreeuwenberg PMM, Fransen MP, Ausems MGEM.
    • Breast. 2021 Aug;58:80-87. doi: 10.1016/j.breast.2021.04.008. Epub 2021 Apr 22.
    • Oncologists' Perceptions of Tumor Genomic Profiling and the Communication of Test Results and Risks.
    • Hall MJ, D'Avanzo P, Chertock Y, Brajuha J, Bass SB.
    • Public Health Genomics. 2021 Jul 29:1-6. doi: 10.1159/000517486. Epub ahead of print.
    • Success Factors and Barriers in Combining Personalized Medicine and Patient Centered Care in Breast Cancer. Results from a Systematic Review and Proposal of Conceptual Framework.
    • de Belvis AG, Pellegrino R, Castagna C, Morsella A, Pastorino R, Boccia S.
    • J Pers Med. 2021 Jul 13;11(7):654. doi: 10.3390/jpm11070654.
    • Knowledge, views and expectations for cancer polygenic risk testing in clinical practice: a cross-sectional survey of health professionals.
    • Smit AK, Sharman AR, Espinoza D, Wallingford C, Young MA, Dunlop K, Tiller J, Newson AJ, Meiser B, Cust AE, Yanes T.
    • Clin Genet. 2021 Jul 3. doi: 10.1111/cge.14025. Epub ahead of print.
    • Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma.
    • Grzelak D.
    • J Adv Pract Oncol. 2021 Jul;12(5):488-491. doi: 10.6004/jadpro.2021.12.5.4. Epub 2021 Jul 1.
    • A Retrospective 5-Year Single Center Study Highlighting the Risk of Cancer Predisposition in Adolescents and Young Adults.
    • Jordan F, Huber S, Sommer S, Schenkirsch G, Frühwald MC, Trepel M, Claus R, Kuhlen M.
    • Cancers (Basel). 2021 Jun 17;13(12):3033. doi: 10.3390/cancers13123033.
    • Germline Genetic Testing for All Patients With Cancer?
    • Nelson R.
    • Medscape Oncology. 2021 Jun 15.
    • Training courses on hereditary breast and ovarian cancer to strengthen cross-sectoral care in underserved areas.
    • Kühn F, Karsten MM, Kendel F, Feufel MA, Speiser D.
    • Patient Educ Couns. 2021 Jun;104(6):1431-1437. doi: 10.1016/j.pec.2020.10.035. Epub 2020 Nov 1.
    • OHSU to Expand Tumor Board Program After Seeing Benefits in Breast Cancer Patients.
    • Kanski A.
    • Precision Oncology News. Disease Areas. 2021 May 24.
    • Perthera, Side-Out Foundation Partner to Advance Precision Oncology in Breast Cancer.
    • [No author given]
    • Precision Oncology News. Cancer Specialties. Breast Cancer. 2021 May 21.
    • Oncologists' perspectives of telephone genetic counseling to facilitate germline BRCA1/2 testing for their patients with high-grade serous ovarian cancer.
    • Hemming P, Kaur R, Meiser B, McKinley J, Young MA, James PA, Forrest LE.
    • J Community Genet. 2021 May 6. doi: 10.1007/s12687-021-00530-7. Epub ahead of print.
    • Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre.
    • Beard C, Monohan K, Cicciarelli L, James PA.
    • Eur J Hum Genet. 2021 May;29(5):872-880. doi: 10.1038/s41431-021-00848-3. Epub 2021 Mar 15.
    • Genetic Testing Challenges in Oncology: BRCA1-Positive Patient Told Paternal Cancer Risk Unimportant.
    • Ray T.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Apr 29.
    • Controversies in Hereditary Cancer Management.
    • AlHilli MM, Pederson HJ.
    • Obstet Gynecol. 2021 Apr 8. doi: 10.1097/AOG.0000000000004364. Epub ahead of print.
    • Genetic Testing Challenges in Oncology: BRCA1-Positive Breast Cancer Patient Told She's Negative.
    • Ray T.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Mar 26.

    Blog post: Genetic Testing Challenges in Oncology: BRCA1-Positive Breast Cancer Patient Told She’s Negative. (My Gene Counsel)

    • Intermountain Gets National Stage, Myriad Adds Tumor Profiling Panel With Combined Test Offering.
    • Ray T.
    • GenomeWeb. Business & Policy. Business News. 2021 Mar 24.
    • News
    • Ovarian cancer risk in Lynch syndrome: it's time to individualise.
    • Ring KL.
    • BJOG. 2021 Mar;128(4):737. doi: 10.1111/1471-0528.16481. Epub 2020 Sep 29.

    Original research:

    A mismatch in care: results of a United Kingdom-wide patient and clinician survey of gynaecological services for women with Lynch syndrome

    • Suprarenal lymphadenectomy with nephrectomy for refractory ovarian cancer.
    • Park SJ, Kim HS.
    • Gland Surg. 2021 Mar;10(3):1268-1270. doi: 10.21037/gs.2020.04.08.
    • Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study.
    • Oosthuizen J, Kotze MJ, Van Der Merwe N, Myburgh EJ, Bester P, van der Merwe NC.
    • Front Oncol. 2021 Feb 12;10:619469. doi: 10.3389/fonc.2020.619469.
    • Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes.
    • Yoon SY, Wong SW, Lim J, Ahmad S, Mariapun S, Padmanabhan H, Hassan NT, Lau SY, Ch'ng GS, Haniffa M, Ong WP, Rethanavelu K, Moey LH, Keng WT, Omar J, Mohd Abas MN, Yong CM, Ramasamy V, Md Noor MR, Aliyas I, Lim MCK, Suberamaniam A, Mat Adenan NA, Ahmad ZA, Ho GF, Abdul Malik R, Subramaniam S, Khoo BP, Raja A, Chin YS, Sim WW, Teh BH, Kho SK, Ong ESE, Voon PJ, Ismail G, Lee CL, Abdullah BZ, Loo KS, Lim CS, Lee SJ, Lim KJL, Shafiee MN, Ismail F, Latiff ZA, Ismail MP, Mohamed Jamli MF, Kumarasamy S, Leong KW, Low J, Md Yusof M, Ahmad Mustafa AM, Mat Ali NH, Makanjang M, Tayib S, Cheah N, Lim BK, Fong CK, Foo YC, Mellor Abdullah M, Tan TS, Chow DSY, Ho KF, Raman R, Radzi A, Deniel A, Teoh DCY, Ang SF, Joseph JK, Ng PHO, Tho LM, Ahmad AR, Muin I, Bleiker E, George A, Thong MK, Woo YL, Teo SH.
    • J Med Genet. 2021 Feb 1:jmedgenet-2020-107416. doi: 10.1136/jmedgenet-2020-107416. Epub ahead of print.
    • Implementation of a High-Risk Breast Clinic for Comprehensive Care of Women With Elevated Breast Cancer Risk Identified by Risk Assessment Models in the Community.
    • Laws A, Mulvey TM.
    • JCO Oncol Pract. 2021 Feb;17(2):e217-e225. doi: 10.1200/OP.20.00256. Epub 2020 Aug 21.
    • Differences in cancer patients' and clinicians' preferences for disclosure of uncertain genomic tumor testing results.
    • Fenton AT, Anderson EC, Scharnetzki E, Reed K, Edelman E, Antov A, Rueter J, Han PKJ; MCGI Working Group.
    • Patient Educ Couns. 2021 Jan;104(1):3-11. doi: 10.1016/j.pec.2020.07.010. Epub 2020 Jul 15.
    • Specialist recommendation for chemoprevention medications in patients at familial risk of breast cancer: a cross-sectional survey in England.
    • Lee SI, Curtis H, Qureshi S, Dutton B, Qureshi N.
    • J Community Genet. 2021 Jan;12(1):111-120. doi: 10.1007/s12687-020-00490-4. Epub 2020 Oct 28.
    • My Gene Counsel and Genomet Announce Product Partnership to Transform Cancer Care Around the Globe.
    • [No author given]
    • My Gene Counsel. Press Releases. 2020 Dec 29.
    • My Gene Counsel, Genomet Develop Decision Support Solution for Precision Cancer Care.
    • [No author given]
    • Precision Oncology News. 2020 Dec 29.
    • Genetic Testing Challenges in Oncology: Woman Without High Breast Cancer Risk Recommended Surgery.
    • Ray T.
    • Precision Oncology News. 2020 Dec 22.
    • BRCA gene testing in women with high-grade serous ovarian carcinoma.
    • Kansu B, Gardner J, Price-Tate R, Murch O, Murray A.
    • J Obstet Gynaecol. 2020 Nov 23:1-4. doi: 10.1080/01443615.2020.1820466. Epub ahead of print.
    • BRCA testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral.
    • Piedimonte S, Power J, Foulkes WD, Weber E, Palma L, Schiavi A, Ambrosio E, Konci R, Gilbert L, Jardon K, Baret L, Zeng X.
    • Int J Gynecol Cancer. 2020 Nov;30(11):1757-1761. doi: 10.1136/ijgc-2020-001261. Epub 2020 Aug 5.
    • "I think that a brief conversation from their provider can go a very long way": Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer.
    • Mallen AR, Conley CC, Fuzzell L, Ketcher D, Augusto BM, McIntyre M, Barton LV, Townsend MK, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST.
    • Support Care Cancer. 2020 Sep 25. doi: 10.1007/s00520-020-05779-1. Epub ahead of print.
    • Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer.
    • Scheinberg T, Goodwin A, Ip E, Linton A, Mak B, Smith DP, Stockler MR, Strach MC, Tran B, Young AL, Zhang AY, Mahon KL, Horvath LG.
    • JCO Oncol Pract. 2020 Sep 24:OP2000399. doi: 10.1200/OP.20.00399. Epub ahead of print.
    • Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices.
    • Watson CH, Soo L, Davidson BA, Havrilesky LJ, Lee PS, McNally LJ, Previs RA, Secord AA, Berchuck A, Kauff ND.
    • Int J Gynecol Cancer. 2020 Aug 23:ijgc-2020-001536. doi: 10.1136/ijgc-2020-001536. Epub ahead of print.
    • Management of early breast cancer during the COVID-19 pandemic in Brazil.
    • Cavalcante FP, Novita GG, Millen EC, Zerwes FP, de Oliveira VM, Sousa ALL, Freitas Junior R.
    • Breast Cancer Res Treat. 2020 Aug 16. doi: 10.1007/s10549-020-05877-y. Epub ahead of print.
    • Somatic Testing and Germline Genetic Status: Implications for Cancer Treatment Decisions and Genetic Counseling.
    • Swan K, Chatham Dougherty K, Wienke Myers S.
    • Current Genetic Medicine Reports. 2020 Aug 13;8:109. doi: 10.1007/s40142-020-00192-w.
    • Review
    • Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
    • Powell CB, Laurent C, Ciaravino G, Garcia C, Han L, Hoodfar E, Karlea A, Kobelka C, Lee J, Littell RD, Roh J, Vay A, Kushi LH.
    • Gynecol Oncol. 2020 Aug 7:S0090-8258(20)33662-3. doi: 10.1016/j.ygyno.2020.07.027. Epub ahead of print.
    • Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study.
    • Bobbili P, Olufade T, DerSarkissian M, Shenolikar R, Yu H, Duh MS, Tung N.
    • Hered Cancer Clin Pract. 2020 Jun 6;18:13. doi: 10.1186/s13053-020-00144-z.
    • Germline Insights from NGS Somatic Testing: Clinical Challenges and Controversies.
    • Matloff ET, Giri VN, Nowak JA, Sotelo J, Silver DP.
    • Precision Oncology News. Resources: Webinars. 2020 Jun 1.
    • How can Australia integrate routine genetic sequencing in oncology: a qualitative study through an implementation science lens.
    • O'Shea R, Rankin NM, Kentwell M, Gleeson M, Salmon L, Tucker KM, Lewis S, Taylor N.
    • Genet Med. 2020 May 28. doi: 10.1038/s41436-020-0838-x. Epub ahead of print.
    • Genetic Testing Challenges in Oncology: Missed Mutations Highlight Somatic, Germline Test Difference.
    • Ray T.
    • Precision Oncology News. 2020 May 26.
    • The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.
    • Gleeson M, Kentwell M, Meiser B, Do J, Nevin S, Taylor N, Barlow-Stewart K, Kirk J, James P, Scott CL, Williams R, Gamet K, Burke J, Murphy M, Antill YC, Pearn A, Pachter N, Ebzery C, Poplawski N, Friedlander M, Tucker KM; Australian Genetic Testing Mainstreaming Collaborative Group.
    • Gynecol Oncol. 2020 May 22:S0090-8258(20)31028-3. doi: 10.1016/j.ygyno.2020.05.001. Epub ahead of print.
    • Molecular Testing Updates and Impact for Clinical Practice.
    • Slane K.
    • NCCN. Continuing Education. 2020 May 8.
    • Mainstream consent programs for genetic counseling in cancer patients: A systematic review.
    • Scheinberg T, Young A, Woo H, Goodwin A, Mahon KL, Horvath LG.
    • Asia Pac J Clin Oncol. 2020 Apr 20. doi: 10.1111/ajco.13334. [Epub ahead of print]
    • NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
    • NCCN Faculty
    • National Comprehensive Cancer Network. Continuing Education. Opens 2020 Apr 10. Exp 2021 Apr 10.
    • Continuing Education course

    Guidelines:

    NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.

    • Current Indications for Consideration of Evaluation for Hereditary Cancer Predisposition Syndromes and How They Can Change Management.
    • Massingham LJ, De Souza A.
    • R I Med J (2013). 2020 Apr 1;103(3):20-24.
    • Review
    • Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.
    • Frey MK, Lee SS, Gerber D, Schwartz ZP, Martineau J, Lutz K, Reese E, Dalton E, Olsen A, Girdler J, Pothuri B, Boyd L, Curtin JP, Levine DA, Blank SV.
    • Gynecol Oncol. 2020 Apr;157(1):280-286. doi: 10.1016/j.ygyno.2020.01.007. Epub 2020 Feb 11.
    • Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers.
    • McCrorie AD, Ashfield S, Begley A, Mcilmunn C, Morrison PJ, Boyd C, Eccles B, Greville-Heygate S, Copson ER, Cutress RI, Eccles DM, Savage KI, McIntosh SA.
    • J Pathol Clin Res. 2020 Apr;6(2):146-153. doi: 10.1002/cjp2.155. Epub 2020 Feb 5.
    • The Ethics of Delivering Precision Medicine-Pretest Counseling and Somatic Genomic Testing.
    • Borno HT, Rider JR, Gunn CM.
    • JAMA Oncol. 2020 Mar 12. doi: 10.1001/jamaoncol.2020.0016. [Epub ahead of print]
    • Commentary
    • Differences in physician opinions about controversial issues surrounding contralateral prophylactic mastectomy (CPM): A survey of physicians from accredited breast centers in the United States.
    • Yao K, Bleicher R, Moran M, Chang C, Dietz J, Stearns V, Connolly J, Sarantou T, Kurtzman S; National Accreditation Program for Breast Centers Data Working Group.
    • Cancer Med. 2020 Mar 11. doi: 10.1002/cam4.2914. [Epub ahead of print]
    • The Provision of Genetic Testing and Related Services in Quebec, Canada.
    • Unim B, De Vito C, Hagan J, Villari P, Knoppers BM, Zawati M.
    • Front Genet. 2020 Mar 4;11:127. doi: 10.3389/fgene.2020.00127. eCollection 2020.
    • Involving patients and their families in deciding to use next generation sequencing: Results from a nationally representative survey of U.S. oncologists.
    • Spees LP, Roberts MC, Freedman AN, Butler EN, Klein WMP, Prabhu Das I, de Moor JS.
    • Patient Educ Couns. 2020 Mar 3. pii: S0738-3991(20)30116-6. doi: 10.1016/j.pec.2020.03.001. [Epub ahead of print]
    • Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil.
    • Achatz MI, Caleffi M, Guindalini R, Marques RM, Nogueira-Rodrigues A, Ashton-Prolla P.
    • JCO Glob Oncol. 2020 Mar;6:439-452. doi: 10.1200/JGO.19.00170.
    • Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC.
    • Iavazzo C, Fotiou A, Tsiatas M, Christopoulou A, Spiliotis J, Sugarbaker P.
    • Pleura Peritoneum. 2020 Feb 26;5(1):20190029. doi: 10.1515/pp-2019-0029.
    • Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management.
    • Rumford M, Lythgoe M, McNeish I, Gabra H, Tookman L, Rahman N, George A, Krell J.
    • Sci Rep. 2020 Feb 25;10(1):3390. doi: 10.1038/s41598-020-60149-5.
    • Despite Barriers, Labs Starting to Report Suspected Cancer Risk Mutations Seen in Tumor Testing.
    • Ray T.
    • GenomeWeb. 2020 Feb 6.
    • The narrative paradox of the BRCA gene: an ethnographic study in the clinical encounters of ovarian cancer patients.
    • Therond C, Lanceley A, Gibbon S, Rahman B.
    • Anthropol Med. 2020 Feb 3:1-16. doi: 10.1080/13648470.2019.1663784. [Epub ahead of print]
    • Oncology Clinic-Based Hereditary Cancer Genetic Testing in a Population-Based Health Care System.
    • Richardson M, Min HJ, Hong Q, Compton K, Mung SW, Lohn Z, Nuk J, McCullum M, Portigal-Todd C, Karsan A, Regier D, Brotto LA, Sun S, Schrader KA.
    • Cancers (Basel). 2020 Feb 3;12(2). pii: E338. doi: 10.3390/cancers12020338.
    • Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N; OPA Working Group.
    • J Natl Cancer Inst. 2020 Feb 1;112(2):161-169. doi: 10.1093/jnci/djz080.

    Letter:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • Risk-Reducing Bilateral Salpingo-Oophorectomy: Assessing the Incidence of Occult Ovarian Cancer and Surgeon Adherence to Recommended Practices.
    • Newcomb LK, Toal CT, Rindos NB, Wang L, Mansuria SM.
    • J Minim Invasive Gynecol. 2020 Jan 9. pii: S1553-4650(20)30037-6. doi: 10.1016/j.jmig.2020.01.004. [Epub ahead of print]
    • Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process.
    • McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, Mould T, Side L, Lanceley A.
    • Int J Gynecol Cancer. 2019 Nov 19. pii: ijgc-2019-000630. doi: 10.1136/ijgc-2019-000630. [Epub ahead of print]
    • Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing.
    • Vlessis K, Purington N, Chun N, Haraldsdottir S, Ford JM.
    • JNCI Cancer Spectr. 2019 Nov 11;4(1):pkz095. doi: 10.1093/jncics/pkz095. eCollection 2020 Feb.
    • Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention.
    • Perri T, Farhadian Y, Friedman E, Korach J.
    • Menopause. 2019 Nov 4. doi: 10.1097/GME.0000000000001432. [Epub ahead of print]
    • Mainstreaming genetic counseling for BRCA testing into oncology clinics - Indian perspective.
    • Verma A, Nag S, Hasan Q, Selvakumar VPP.
    • Indian J Cancer. 2019 Nov;56(Supplement):S38-S47. doi: 10.4103/ijc.IJC_458_19.
    • Patterns and Predictors of Genetic Referral among Ovarian Cancer Patients at a National Cancer Institute Comprehensive Cancer Center.
    • Mallen AR, Conley CC, Townsend MK, Wells A, Boac BM, Todd S, Gandhi A, Kuznicki M, Augusto BM, McIntyre M, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST.
    • Clin Genet. 2019 Oct 10. doi: 10.1111/cge.13654. [Epub ahead of print]
    • BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.
    • Capoluongo E, Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.
    • Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.
    • When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?
    • DeLeonardis K, Hogan L, Cannistra SA, Rangachari D, Tung N.
    • J Oncol Pract. 2019 Sep;15(9):465-473. doi: 10.1200/JOP.19.00201.

    Commentary:

    Tumor Genomic Sequencing as an Impetus to Screen for Germline Mutations: Primum Non Nocere.

    Commentary:

    Personalized Medicine, Genomic Profiling and Germline Mutations: Toward More Precise Decisions.

    • Health Care Provider Adherence to Surgical Guidelines for Risk-Reducing Salpingo-Oophorectomy.
    • Wilhite AM, Oestreich MC, Olson M, Bedell SM, Westenberg D, Bangdiwala A, Ikramuddin S, Sanchez-Avila M, Madoff RD, Khalifa MA, Erickson BK.
    • Obstet Gynecol. 2019 Sep;134(3):520-526. doi: 10.1097/AOG.0000000000003421.
    • Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.
    • Casasanta N, Kipnis ST, Linville L, Lipinski S, Knoedler A, Marino A, McHenry A, Biagi T, Stark E, Amdur R, Denduluri N, Rodriguez P, Isaacs C, Kaltman R.
    • Clin Breast Cancer. 2019 Aug 21. pii: S1526-8209(19)30646-9. doi: 10.1016/j.clbc.2019.07.004. [Epub ahead of print]
    • Participation in a Novel Trial Assessing Prophylactic Breast Irradiation: The Importance of Input from the Radiation Oncologist.
    • Evron E, Goldberg H, Ben-David MA, Corn BW.
    • Int J Radiat Oncol Biol Phys. 2019 Aug 10. pii: S0360-3016(19)33636-3. doi: 10.1016/j.ijrobp.2019.08.004. [Epub ahead of print]
    • The implications of genetic testing on radiotherapy decisions: a guide for radiation oncologists.
    • Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, Bernstein JL, Evans JD, Gerber NK, Kerns SL, Keen J, Litton JK, Reiner AS, Riaz N, Rosenstein BS, Sawakuchi GO, Shaitelman SF, Powell SN, Woodward WA.
    • Int J Radiat Oncol Biol Phys. 2019 Aug 2. pii: S0360-3016(19)33530-8. doi: 10.1016/j.ijrobp.2019.07.026. [Epub ahead of print]
    • Review
    • From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin.
    • Pujol P, De La Motte Rouge T, Penault-Llorca F.
    • Diagnostics (Basel). 2019 Jul 26;9(3). pii: E83. doi: 10.3390/diagnostics9030083.
    • Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Prostate Cancer
    • Srinivas S, Shah SA.
    • NCCN Continuing Education. 2019 Jul 5.
    • CME Course
    • Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care.
    • Hallowell N, Wright S, Stirling D, Gourley C, Young O, Porteous M.
    • Fam Cancer. 2019 Jul;18(3):293-301. doi: 10.1007/s10689-019-00122-y.
    • Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers.
    • Swink A, Nair A, Hoof P, Matthews A, Burden C, Johnson K, Blum JL.
    • Proc (Bayl Univ Med Cent). 2019 Jun 11;32(3):340-344. doi: 10.1080/08998280.2019.1612702. eCollection 2019 Jul.
    • A Simple Way to Make Genetic Counseling More Efficient and Accessible.
    • Markman M.
    • Medscape Oncology. 2019 Jun 14.

    Original research:

    Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study.

    • How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations?
    • Markman M.
    • Medscape Oncology. 2019 Jun 14.

    Original research:

    Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.

    • Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    • Boitano TKL, Barrington DA, Batra S, McGwin G Jr, Turner TB, Farmer MB, Brown AM, Straughn MJ Jr, Leath CA 3rd.
    • Gynecol Oncol. 2019 Jun 10. pii: S0090-8258(19)31275-2. doi: 10.1016/j.ygyno.2019.05.031. [Epub ahead of print]
    • Breast Cancer Risk Prediction Models: Challenges in Clinical Application.
    • Paquin M, Fasolino T, Steck MB.
    • Clin J Oncol Nurs. 2019 Jun 1;23(3):256-259. doi: 10.1188/19.CJON.256-259.
    • Review
    • Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers.
    • George A.
    • Curr Genet Med Rep. 2019 Jun;7(2):116-123. doi: 10.1007/s40142-019-00167-6. Epub 2019 May 9.
    • Review
    • Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N.
    • J Natl Cancer Inst. 2019 May 11. pii: djz080. doi: 10.1093/jnci/djz080. [Epub ahead of print]

    Letter, Comment:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
    • Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, Warren-Perry M, Eccleston A, Tan MM, Teo SH, Turner N, Strydom A, George A, Rahman N.
    • JAMA Netw Open. 2019 May 3;2(5):e194428. doi: 10.1001/jamanetworkopen.2019.4428.
    • [Genetic Approach of Breast Cancer].
    • Takei J, Yamauchi H.
    • Gan To Kagaku Ryoho. 2019 May;46(5):831-837.
    • Review, [Article in Japanese]
    • Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer.
    • Rotter J, Wilson L, Greiner MA, Pollack CE, Dinan M.
    • Breast Cancer Res Treat. 2019 Apr 26. doi: 10.1007/s10549-019-05248-2. [Epub ahead of print]
    • Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
    • Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan C, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN; PCCTC Germline Genetics Working Group.
    • Clin Genitourin Cancer. 2019 Apr 18. pii: S1558-7673(19)30139-9. doi: 10.1016/j.clgc.2019.04.013. [Epub ahead of print]
    • BRCA mutation testing for ovarian cancer in the context of available targeted therapy: Survey and consensus of Hong Kong specialists.
    • Kwong A, Cheng KD, Hsue CV, Hui SK, Leung CR, Leung KA, Ngan KR, Soong SI.
    • Asia Pac J Clin Oncol. 2019 Mar;15 Suppl 2:20-31. doi: 10.1111/ajco.13116. Epub 2019 Mar 6.
    • Mainstreamed genetic testing for women with ovarian cancer: first-year experience.
    • Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, Mould T, Side L.
    • J Med Genet. 2019 Mar;56(3):195-198. doi: 10.1136/jmedgenet-2017-105140. Epub 2018 Mar 13.
    • Negotiating jurisdictional boundaries in response to new genetic possibilities in breast cancer care: The creation of an 'oncogenetic taskscape'.
    • Wright S, Porteous M, Stirling D, Young O, Gourley C, Hallowell N.
    • Soc Sci Med. 2019 Mar;225:26-33. doi: 10.1016/j.socscimed.2019.02.020. Epub 2019 Feb 13.
    • NCCN Guidelines® Insights - Breast Cancer, Version 3.2018.
    • Faculty
    • National Comprehensive Cancer Network. Continuing Education. 2019 Feb 2.
    • CME course

    Guidelines: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer — Version 4.2018 — February 8, 2019 (PDF) (National Comprehensive Cancer Network)

    • Genetic Service Delivery Models: Exploring Approaches to Care for Families With Hereditary Cancer Risk.
    • Pierle JM, Mahon SM.
    • Clin J Oncol Nurs. 2019 Feb 1;23(1):60-67. doi: 10.1188/19.CJON.60-67.
    • Optimise not compromise: The importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery.
    • Strach MC, Prasanna T, Kirova YM, Alran S, O'Toole S, Beith JM, Poortmans P, McNeil CM, Carroll S.
    • Crit Rev Oncol Hematol. 2019 Feb;134:10-21. doi: 10.1016/j.critrevonc.2018.11.007. Epub 2018 Nov 30.
    • Review
    • Assessing the medical workforces perceived barriers to the prescription of risk-reducing medication for women at high-risk of breast cancer.
    • Sutherland S, Meiser B, Kaur R, Mitchell G, Kirk J, Peate M, Tim Wong WK, Goodwin A.
    • Breast J. 2019 Jan;25(1):34-40. doi: 10.1111/tbj.13157. Epub 2018 Dec 7.
    • Clinicians' use of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey.
    • Brédart A, Kop JL, Antoniou AC, Cunningham AP, De Pauw A, Tischkowitz M, Ehrencrona H, Schmidt MK, Dolbeault S, Rhiem K, Easton DF, Devilee P, Stoppa-Lyonnet D, Schmutlzer R.
    • J Community Genet. 2019 Jan;10(1):61-71. doi: 10.1007/s12687-018-0362-8. Epub 2018 Mar 5.
    • BRCA Testing Dichotomy in Saudi Arabia.
    • Abusanad A.
    • J Glob Oncol. 2019 Jan;(5):1-2. doi: 10.1200/JGO.18.00188.
    • No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer.
    • Jacobson M, Bernardini M, Sobel ML, Kim RH, McCuaig J, Allen L.
    • J Obstet Gynaecol Can. 2018 Nov;40(11):1497-1510. doi: 10.1016/j.jogc.2018.05.046.
    • Guidelines

    [Article in French]:

    No 366 - Prise en charge gynécologique du cancer du sein et de l'ovaire héréditaire.

    • Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists.
    • Murciano-Goroff YR, McCarthy AM, Bristol MN, Groeneveld P, Domchek SM, Motanya UN, Armstrong K.
    • Breast Cancer Res Treat. 2018 Aug;171(1):173-180. doi: 10.1007/s10549-018-4810-2. Epub 2018 May 8.
    • Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.
    • Uyar D, Neary J, Monroe A, Nugent M, Simpson P, Geurts JL.
    • Gynecol Oncol. 2018 Jun;149(3):565-569. doi: 10.1016/j.ygyno.2018.03.059. Epub 2018 Apr 10.
    • Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
    • Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, Van Le L, Ghamande S, González-Santiago S, Bover I, Graña Suárez B, Green A, Huot-Marchand P, Bourhis Y, Karve S, Blakeley C.
    • J Clin Oncol. 2018 May 1;36(13):1300-1307. doi: 10.1200/JCO.2017.76.2781. Epub 2018 Mar 20.
    • Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
    • Shaw J, Bulsara C, Cohen PA, Gryta M, Nichols CB, Schofield L, O'Sullivan S, Pachter N, Hardcastle SJ.
    • Patient Educ Couns. 2018 May;101(5):938-944. doi: 10.1016/j.pec.2017.12.011. Epub 2017 Dec 12.
    • Practical consensus recommendation on when to do BRCA testing.
    • Parikh PM, Wadhwa J, Minhas S, Gupta A, Mittal S, Ranjan S, Mehta P, Singh R, Kataria SP, Salim S, Ahmed M, Aggarwal S.
    • South Asian J Cancer. 2018 Apr-Jun;7(2):106-109. doi: 10.4103/sajc.sajc_112_18.
    • Practical consensus recommendations on management of triple-negative metastatic breast cancer.
    • Rangarao R, Smruti BK, Singh K, Gupta A, Batra S, Choudhary RK, Gupta A, Sahani S, Kabra V, Parikh PM, Aggarwal S.
    • South Asian J Cancer. 2018 Apr-Jun;7(2):127-131. doi: 10.4103/sajc.sajc_118_18.
    • Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer.
    • Bhattacharyya GS, Walia M, Nandi M, Murli A, Salim S, Rajpurohit S, Shinde S, Aggarwal S, Parikh PM.
    • South Asian J Cancer. 2018 Apr-Jun;7(2):156-158. doi: 10.4103/sajc.sajc_126_18.
    • Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
    • Swanson CL, Kumar A, Maharaj JM, Kemppainen JL, Thomas BC, Weinhold MR, Slaby KM, Mara KC, Wick MJ, Bakkum-Gamez JN.
    • Gynecol Oncol. 2018 Apr;149(1):121-126. doi: 10.1016/j.ygyno.2018.01.033. Epub 2018 Feb 3.
    • Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.
    • Liang MI, Wong DH, Walsh CS, Farias-Eisner R, Cohen JG.
    • J Genet Couns. 2018 Feb;27(1):177-186. doi: 10.1007/s10897-017-0135-2. Epub 2017 Aug 7.
    • Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families.
    • Vicuña B, Delaney HD, Flores KG, Ballinger L, Royce M, Dayao Z, Pal T, Kinney AY.
    • J Community Genet. 2018 Jan;9(1):81-92. doi: 10.1007/s12687-017-0322-8. Epub 2017 Oct 2.
    • SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine.
    • Warner JL, Prasad I, Bennett M, Arniella M, Beeghly-Fadiel A, Mandl KD, Alterovitz G.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00292. Epub 2018 May 1.
    • "Best practices in risk reducing bilateral salpingo-oophorectomy: the influence of surgical specialty".
    • Malacarne DR, Boyd LR, Long Y, Blank SV.
    • World J Surg Oncol. 2017 Dec 11;15(1):218. doi: 10.1186/s12957-017-1282-5.
    • Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists.
    • Audibert C, Perlaky A, Stuntz M, Glass D.
    • Drug Des Devel Ther. 2017 Dec 6;11:3471-3479. doi: 10.2147/DDDT.S151420. eCollection 2017.
    • Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer.
    • Lee YC, Bressel M, Grant P, Russell P, Smith C, Picken S, Camm S, Kiely BE, Milne RL, McLachlan SA, Hickey M, Friedlander ML, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
    • Fam Cancer. 2017 Oct;16(4):461-469. doi: 10.1007/s10689-017-9977-x.
    • Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care.
    • Senter L, O'Malley DM, Backes FJ, Copeland LJ, Fowler JM, Salani R, Cohn DE.
    • Gynecol Oncol. 2017 Oct;147(1):110-114. doi: 10.1016/j.ygyno.2017.07.141. Epub 2017 Aug 8.
    • Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?
    • Partridge AH, Sepucha K, O'Neill A, Miller KD, Baker E, Dang CT, Northfelt DW, Sledge GW, Schneider BP.
    • Breast Cancer Res Treat. 2017 Jun 23. doi: 10.1007/s10549-017-4338-x. [Epub ahead of print]
    • Practice Patterns of Hereditary Ovarian Cancer Management in Korea.
    • Choi MC, Lim MC, Lee M, Kim MK, Suh DH, Song YJ, Kim TJ, Chang SJ, Kim JW.
    • Int J Gynecol Cancer. 2017 Jun;27(5):895-899. doi: 10.1097/IGC.0000000000000964.
    • Genomic Testing and Precision Medicine in Cancer Care.
    • West HJ, Miller G.
    • Medscape. News & Perspective. 2017 May 2.
    • Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences.
    • Kurian AW, Friese CR, Bondarenko I, Jagsi R, Li Y, Hamilton AS, Ward KC, Katz SJ.
    • JAMA Oncol. 2017 Mar 1;3(3):391-397. doi: 10.1001/jamaoncol.2016.5652.
    • Assessing, Counseling, and Treating Patients at High Risk for Breast Cancer.
    • Clifford E, Hughes KS, Roberts M, Pirzadeh-Miller S, McLaughlin SA.
    • Ann Surg Oncol. 2016 Oct;23(10):3128-32. doi: 10.1245/s10434-016-5399-5. Epub 2016 Jul 11.
    • Review
    • All women with ovarian cancer should be offered genetic testing – so why aren’t they?
    • Emma Smith
    • Science Blog. Cancer Research UK. 2016 Aug 17.
    • A cost analysis of a cancer genetic service model in the UK.
    • Slade I, Hanson H, George A, Kohut K, Strydom A, Wordsworth S, Rahman N; MCG programme.
    • J Community Genet. 2016 Jul;7(3):185-94. doi: 10.1007/s12687-016-0266-4. Epub 2016 Feb 27.
    • Patient-Centered Communication for Discussing Oncotype DX Testing.
    • Roberts MC, Bryson A, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Wheeler SB.
    • Cancer Invest. 2016 May 27;34(5):205-12. doi: 10.3109/07357907.2016.1172637. Epub 2016 Apr 28.

    Comments from NSGC General Discussion Forum

    Subject: Cancer Investigation Journal- Article needed

    • Beyond BRCA: A Pilot Program to Assess and Improve Knowledge of Pharmacogenomic Testing Among Advanced Practitioners in a Breast Cancer Treatment Setting.
    • Hoffman SL, Reid Kaufman RR, Ferrari S, Alexander SA, Rosenzweig MQ, Wesmiller SW.
    • J Adv Pract Oncol. 2016 May-Jun;7(4):382-389. Epub 2016 May 1.
    • The genetic prediction of risk for gynecologic cancers.
    • Randall LM, Pothuri B.
    • Gynecol Oncol. 2016 Apr;141(1):10-6. doi: 10.1016/j.ygyno.2016.03.007.
    • Review
    • Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond.
    • Hall MJ, Obeid EI, Schwartz , Mantia-Smaldone G, Forman AD, Daly MB.
    • Gynecol Oncol. 2016 Mar;140(3):565-74. doi: 10.1016/j.ygyno.2016.01.019. Epub 2016 Jan 23.
    • Review
    • Genomic testing and precision medicine - What does this mean for gynecologic oncology?
    • Liu J, Konstantinopoulos PA, Matulonis UA.
    • Gynecol Oncol. 2016 Jan;140(1):3-5. doi: 10.1016/j.ygyno.2015.12.001. Epub 2015 Dec 4.
    • Understanding of BRCA VUS genetic results by breast cancer specialists.
    • Eccles BK, Copson E, Maishman T, Abraham JE, Eccles DM.
    • BMC Cancer. 2015 Nov 25;15(1):936. doi: 10.1186/s12885-015-1934-1.
    • Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center.
    • Parker BA, Schwaederlé M, Scur MD, Boles SG, Helsten T, Subramanian R, Schwab RB, Kurzrock R.
    • J Oncol Pract. 2015 Nov;11(6):442-9. doi: 10.1200/JOP.2015.004127. Epub 2015 Aug 4.
    • BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.
    • Eccles DM, Mitchell G, Monteiro AN, Schmutzler R, Couch FJ, Spurdle AB, Gómez-García EB; ENIGMA Clinical Working Group.
    • Ann Oncol. 2015 Oct;26(10):2057-65. doi: 10.1093/annonc/mdv278. Epub 2015 Jul 7.
    • Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer.
    • Wang F, Amara D, Peled AW, Sbitany H, Foster RD, Ewing CA, Alvarado M, Esserman LJ.
    • Ann Surg Oncol. 2015 Oct;22(10):3338-45. doi: 10.1245/s10434-015-4745-3. Epub 2015 Jul 28.
    • Alison's Story-A Cautionary Tale in the Age of Genomic Medicine.
    • Burn J.
    • Surg Oncol Clin N Am. 2015 Oct;24(4):635-637. doi: 10.1016/j.soc.2015.06.010. Epub 2015 Aug 14.
    • Review
    • A Rare Case of BRCA2-Associated Breast Cancer in Pregnancy.
    • Leidhin CN, Heeney A, Connolly C, Swan N, Foster A, Geraghty J.
    • Ir Med J. 2015 Jul-Aug;108(7):217-8.
    • Referral of Ovarian Cancer Patients for Genetic Counselling by Oncologists: Need for Improvement.
    • Ricci MT, Sciallero S, Mammoliti S, Gismondi V, Franiuk M, Bruzzi P, Varesco L.
    • Public Health Genomics. [2015 Jul;]18(4):225-32. doi: 10.1159/000431352. Epub 2015 Jun 24.
    • Provider perspectives on presenting risk information and managing worry about recurrence among breast cancer survivors.
    • Janz NK, Leinberger RL, Zikmund-Fisher BJ, Hawley ST, Griffith K, Jagsi R.
    • Psychooncology. 2015 May;24(5):592-600. doi: 10.1002/pon.3625. Epub 2014 Jul 23.
    • Genetic counseling for hereditary breast and gynecologic cancer syndromes at a community hospital.
    • Haber KM, Seagle BL, Drew B, Morrill-Cornelius S, Samuelson R, Hostmeyer S, Shahabi S.
    • Conn Med. 2014 Aug;78(7):417-20.
    • Inadequate Family History Assessment by Oncologists is an Important Physician Barrier to Referral for Hereditary Breast Cancer Evaluation.
    • Ow SG, Yong YF, Chieng WS, Phyu PS, Lee SC.
    • Clin Oncol (R Coll Radiol). 2014 Mar;26(3):174-5. doi: 10.1016/j.clon.2013.11.029. Epub 2014 Jan 4.
    • Letter
    • Clinical cancer genetics. Part 2: Breast.
    • Pollock J, Welsh JS.
    • Am J Clin Oncol. 2014 Feb;37(1):86-9. doi: 10.1097/COC.0b013e31823fe657.
    • Review
    • New genetic testing pathway for cancer patients.
    • Philippa Brice.
    • PHG Foundation, 2014 Jan 24.
    • Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives.
    • Spellman E, Sulayman N, Eggly S, Peshkin BN, Isaacs C, Schwartz MD, O'Neill SC.
    • Psychooncology. 2013 Sep;22(9):2110-6. doi: 10.1002/pon.3264. Epub 2013 Feb 28.
    • Oncology health professionals' attitudes toward treatment-focused genetic testing for women newly diagnosed with breast cancer.
    • Burcher S, Meiser B, Mitchell G, Saunders C, Rahman B, Tucker K, Barlow-Stewart K, Watts K, Gleeson M, Kirk J.
    • Per Med. 2013 Jul;10(5):431-440. doi: 10.2217/pme.13.45.
    • Interest and attitudes of patients, cancer physicians, medical students and cancer researchers towards a spectrum of genetic tests relevant to breast cancer patients.
    • Ngoi N, Lee SC, Hartman M, Khin LW, Wong A.
    • Breast. 2013 Feb;22(1):47-52. doi: 10.1016/j.breast.2012.04.003. Epub 2012 May 4.
    • Managing patients at high risk for hereditary breast cancer: a guide for the practicing physician.
    • Cusack JC Jr, Hughes KS.
    • Ann Surg Oncol. 2012 Jun;19(6):1721-2. doi: 10.1245/s10434-012-2255-0.
    • Hereditary gynecologic cancers: risk assessment, counseling, testing and management.
    • Ballinger LL.
    • Obstet Gynecol Clin North Am. 2012 Jun;39(2):165-81. doi: 10.1016/j.ogc.2012.02.006.
    • Review
    • Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern Ontario.
    • Vanstone M, Chow W, Lester L, Ainsworth P, Nisker J, Brackstone M.
    • Can Fam Physician. 2012 May;58(5):e258-66.